Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331
Ann. Oncol 2021 Feb 01;[EPub Ahead of Print], DR Spigel, D Vicente, TE Ciuleanu, S Gettinger, S Peters, L Horn, C Audigier-Valette, NP Aranda, O Juan-Vidal, Y Cheng, H Zhang, M Shi, A Luft, J Wolf, S Antonia, K Nakagawa, J Fairchild, C Baudelet, D Pandya, P Doshi, H Chang, M ReckFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.